Scholar Rock Holding (SRRK) Equity Average (2018 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Equity Average of $260.8 million in Q1 2026, up 6.32% quarter-over-quarter from $245.2 million in Q4 2025, and down 23.42% on a YoY basis from $340.5 million in Q1 2025.
Scholar Rock Holding (SRRK) Equity Average (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Equity Average history runs 9 years deep, the most recent figure standing at $260.8 million for Q1 2026.
- In Q1 2026, Equity Average fell 23.42% year-over-year to $260.8 million; the TTM figure through Mar 2026 stood at $260.8 million (down 23.42% YoY), while the FY2025 annual figure was $307.1 million, up 3.41% from the prior year.
- Equity Average was $260.8 million for Q1 2026 at Scholar Rock Holding, up from $245.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $340.5 million in Q1 2025 to a low of $106.4 million in Q3 2024.
- Historically, Equity Average has averaged $229.6 million across 5 years, with a median of $239.1 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Equity Average tumbled 42.51% in 2024, then surged 124.74% in 2025.
- A 5-year view of Equity Average shows it stood at $276.8 million in 2022, then slipped by 29.02% to $196.4 million in 2023, then advanced by 13.99% to $223.9 million in 2024, then increased by 9.52% to $245.2 million in 2025, then gained by 6.32% to $260.8 million in 2026.
- The last three Equity Average figures came in at $260.8 million (Q1 2026), $245.2 million (Q4 2025), and $239.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 260.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 260.75 Mn |
| Dec 31, 2025 | 245.24 Mn |
| Sep 30, 2025 | 239.14 Mn |
| Jun 30, 2025 | 272.81 Mn |
| Mar 31, 2025 | 340.48 Mn |
| Dec 31, 2024 | 223.92 Mn |
| Sep 30, 2024 | 106.41 Mn |
| Jun 30, 2024 | 158.20 Mn |
| Mar 31, 2024 | 204.00 Mn |
| Dec 31, 2023 | 196.44 Mn |
| Sep 30, 2023 | 185.08 Mn |
| Jun 30, 2023 | 215.58 Mn |
| Mar 31, 2023 | 244.44 Mn |
| Dec 31, 2022 | 276.75 Mn |
| Sep 30, 2022 | 311.39 Mn |
| Jun 30, 2022 | 250.41 Mn |
| Mar 31, 2022 | 171.70 Mn |
| Dec 31, 2021 | 179.67 Mn |
| Sep 30, 2021 | 201.96 Mn |
| Jun 30, 2021 | 228.60 Mn |